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Pharmacological Mobilization of Endogenous Stem
Cells Significantly Promotes Skin Regeneration after
Full-Thickness Excision: The Synergistic Activity of
AMD3100 and Tacrolimus
Qing Lin1, Russell N. Wesson1, Hiromichi Maeda1, Yongchun Wang1, Zhu Cui1, Jun O. Liu2,
Andrew M. Cameron1, Bin Gao3, Robert A. Montgomery1, George M. Williams1 and Zhaoli Sun1
Stem cell therapy has shown promise in treating a variety of pathologies including skin wounds, but practical
applications remain elusive. Here, we demonstrate that endogenous stem cell mobilization produced by
AMD3100 and low-dose tacrolimus is able to reduce by 25% the time of complete healing of full-thickness
wounds created by surgical excision. Equally important, healing was accompanied by reduced scar formation and
regeneration of hair follicles. Searching for mechanisms, we found that AMD3100 combined with low-dose
tacrolimus mobilized increased number of lineage-negative c-Kitþ , CD34þ , and CD133þ stem cells. Low-dose
tacrolimus also increased the number of SDF-1-bearing macrophages in the wound sites amplifying the ‘‘pull’’ of
mobilized stem cells into the wound. Lineage tracing demonstrated the critical role of CD133 stem cells in
enhanced capillary and hair follicle neogenesis, contributing to more rapid and perfect healing. Our findings
offer a significant therapeutic approach to wound healing and tissue regeneration.
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INTRODUCTION
Every year, in the United States, more than 1.25 million
people suffer burns and 6.5 million have chronic skin ulcers
caused by pressure, venous stasis, or diabetes mellitus (Singer
and Clark, 1999). The treatment of these conditions remains
imperfect and expensive. There is hope that stem cell therapy
may prove beneficial as it has been increasingly well
established that stem cells have an important role in wound
healing. For example, artificial skin substitutes have been
shown to be more effective when stem cells are incorporated
into these membranes. The quality of burn wound healing
improves (Leonardi et al., 2012), reducing scar formation and
reestablishing the skin appendages (Mansilla et al., 2010;
Tamai et al., 2011; Huang and Burd, 2012). The treatment of a
chronic static diabetic ulcer has been improved by using the
patient’s bone marrow (BM) mesenchymal stem cells (MSCs)
in combination with autologous skin fibroblasts embedded
on a biodegradable collagen membrane (Coladerm; Vojtassa´k
et al., 2006). BM cells from both embryonic and postnatal
sources have been shown to repair genetic defects in collagen
synthesis and basement membrane defects, thereby promoting
skin wound healing (Chino et al., 2008; Tolar et al., 2009;
Fujita et al., 2010). Recently, a clinical trial found that
allogeneic whole-BM transplantation in humans suffering
from a blistering skin disorder caused by the lack of Col 7
resulted in the restoration of skin integrity and Col 7
expression in basement membranes (Wagner et al., 2010).
Many basic cellular studies have also emphasized the
plastic relationships between skin and BM. Fibroblast-like
cells in the dermis having hematopoietic and mesenchymal
lineages are derived from BM, and the number of these
cells increases after skin wounding (Fathke et al., 2004; Ishii
et al., 2005). Donor cells have replaced some keratinocytes
after BM transplantation and have persisted in the epidermis
for at least 3 years (Ko¨rbling et al., 2002). BM cells contribute
to fetal skin development as infusion of green fluorescent
protein (GFP) BM cells in utero in mice led to the
accumulation of GFP-positive cells in the developing dermis,
particularly in association with developing hair follicles
(Chino et al., 2008).
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These abundant studies document the importance of BM
stem cells in wound healing and raise the tantalizing possibi-
lity that cellular processes can be harnessed to develop
practical therapeutic protocols to treat large full-thickness
burns and massive soft tissue injuries, which demand immedi-
ate therapy. The promise of improved wound repair by
harnessing stem cells is testified by the existence of 90 clinical
trials using MSC-based therapies listed in the NIH registry
(Cerqueira et al., 2012).
To avoid the preparation of endogenous stem cells, which is
expensive and time-consuming, we proposed in these studies
to mobilize endogenous stem cells pharmacologically with
AMD3100 and tacrolimus. AMD3100 has been shown to
drive endogenous stem cells from the BM to the bloodstream
in both animals and man (Hendrix et al., 2000; Liles et al.,
2003; Devine et al., 2004; Broxmeyer et al., 2005; Hisada
et al., 2012). Tacrolimus in low dosages proved to have
synergistic effects (Okabayashi et al., 2011), and combination
treatment promised a simple, safe, and rapid means of
presenting stem cells to injured areas. Here, we test this
hypothesis in the healing of full-thickness skin wounds in mice
and rats. On finding that this treatment was able to reduce the
time for complete healing by 25%, we characterized stem/
progenitor cells and related cytokines/growth factors in the
wound and substantiated the important role of mobilized
CD133þ stem cells in angiogenesis and hair follicle regene-
ration in wound areas using lineage tracing.
RESULTS
AMD3100 plus low-dose tacrolimus accelerated wound healing
after full-thickness skin excision
Four full-thickness wounds were generated by 5 mm diameter
circular excisions on the shaved back of a wild-type C57/B6
mouse (Figure 1a). Each wound site was photographed
digitally at the indicated time intervals, and wound areas
were calculated using Adobe Photoshop software. Changes
in wound areas over time were expressed as the percentage
of the initial wound areas (Figure 1b). Wounded mice were
divided randomly into four experimental groups as follows
and received subcutaneous injections of saline or drugs
immediately after wounding until complete healing: (1) con-
trol group treated with saline; (2) tacrolimus group treated
daily with low-dose (0.1 mg kg1); (3) AMD3100 group
treated every other day (1.0 mg kg1); and (4) combination
group given low-dose tacrolimus and AMD3100. All wound
evaluations were double blinded.
Wounds reached complete closure on day 12 after surgery
in group 1 (n¼ 6; Figure 1c and d), which is consistent with
the known healing kinetics in this established model
(Shinozaki et al., 2009; Mack et al., 2012). The six animals
treated with tacrolimus or AMD3100 alone exhibited
significantly, but only moderate, faster healing compared
with the saline control group (Figure 1d) as wounds reached
complete closure at day 11. The healing time was reduced to
9 days or by 25% in the group four mice treated with
AMD3100 plus low-dose tacrolimus. Digital images showed
that treatment with dual drug therapy had significant effects
reducing the size of the skin defect as soon as day 5
(Figure 1d), which was the start of the re-epithelialization
phase of wound healing. Macroscopically, minimal ulceration
and early epithelial ingrowth were observed at the skin
boarders on post-wounding day 5 in the dual drug–treated
group, whereas wounds in the other three groups showed
little, if any, epithelialization and continued ulceration
(Figure 1c and h). We repeated these studies in rats and found
that rats receiving dual drug therapy also showed an equiva-
lent effect, significantly reducing the time for complete healing
from 18 to 13 days or by 28% (Supplementary Figure S1
online).
Mouse skin is mobile, and contraction accounts for a large
part of wound closure. To deter this mechanism, we per-
formed the excisional wound–splinting model in which a
splinting ring is bonded tightly to the skin around the wound
(Figure 1e). The wound therefore heals through granulation
and re-epithelialization, a process similar to the healing of
most human skin defects. We found that wound repair was
accelerated in the splinted wounds treated with low-dose
tacrolimus or AMD3100 monotherapy compared with the
control (saline) group, whereas the most accelerated healing
was found in animals receiving dual treatment (Figure 1f
and g). Thus, the therapeutic effects of AMD3100 plus
low-dose tacrolimus were primarily on skin wound epithelia-
lization. Other groups of mice were treated with high-dose
AMD3100 (5.0 mg kg1) or tacrolimus (1.0 mg kg1) and
we found that high-dose tacrolimus impeded skin wound
healing, whereas increased dosage of AMD3100 showed no
significant difference (Supplementary Figure S2 online).
AMD3100 plus low-dose tacrolimus ameliorated scar formation
and promoted hair follicle regeneration
Dermal wound repair commences with the arrest of hemor-
rhage, followed by an inflammatory response, formation of
granulation tissue within the wound space, fibrosis, and re-
epithelization of the wound culminating in the production of a
scar.
Histologically, the re-epithelialized wound in the control
groups on day 15 showed a disorganized epidermis, with
blurring of the boundary between the epidermis and the
dermis (Figure 2b). There were few hair follicles in the group
1, 2, and 3 mice and the collagen was abundant and
disorganized (Figure 2c), which is in agreement with the
results of published studies (Devine et al., 2004). By contrast,
the dual drug–treated animals had a thin and well-organized
epidermis with well-formed hair follicles and much better
organized collagen (Figure 2b and c; lower panels). The most
striking finding was that hair appeared only in the re-
epithelialized wound in the dual drug–treated animals after
15 days (Figure 2a and d). Not surprisingly, the number of hair
follicles in the tissue sections of re-epithelialized wound was
significantly higher in the dual drug–treated animals compared
with the control groups (Figure 2e). We found that dual drug
treatment also stimulated hair follicle neogenesis and reduced
scarring in rats (Supplementary Figure S3 online). Thus, the
combination of low-dose tacrolimus and AMD3100 improved
wound healing by promoting both re-epithelialization and
differentiation of skin components.
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AMD3100 and low-dose tacrolimus synergistically mobilized
lineage-negative cells bearing stem cell markers for c-Kitþ ,
CD34þ , and CD133þ , whereas low-dose tacrolimus increased
the number of SDF-1-producing macrophages
We performed flow cytometry on blood samples to determine
the stem cell constituents mobilized by treatment with
AMD3100 and tacrolimus. The numbers of lineage-negative,
c-Kit, CD34þ , CD133þ cells, and lineage-negative Triple-
positive (c-Kitþ CD34þ CD133þ ) cells were significantly
greater in peripheral blood (Figure 3a) in the animals receiving
combination drug treatment at 5 days after injury. Immuno-
fluorescence staining of wound tissue sections showed that the
number of CD133þ cells was increased by combination treat-
ment as were c-Kitþ and CD34þ cells (Figure 3b). These
cells were found particularly in newly formed granulation
tissues of the wounds. Interestingly, at this 5-day time point,
many CD133þ cells co-stained with CD31, a marker of endo-
thelial cells (Figure 3b; right panels). The number of CD133þ
cells declined at day 7, but remained detectable at day 9 after
wound closure. In contrast, CD31þ cells increased in a time-
dependent fashion (Supplementary Figure S4 online).
Semiquantitative PCR analysis of the granulation tissues
showed that mRNA expression of the attractor molecule,
stromal cell–derived factor (SDF)-1 and stem cell marker
CD133 were significantly increased in the group 4 mice
compared with groups 1, 2, and 3 at 5 days after wounding
(Figure 4a and b). Immunofluorescence staining demonstrated
that the number of cells having SDF-1 and F4/80 (a marker of
macrophages) markers was significantly greater in wound sites
in the animals receiving low-dose tacrolimus alone or those
receiving dual drug treatment at 5 days after injury (Figure 4c).
Interestingly, SDF-1 co-stained with some of the F4/80þ cells
indicating that these macrophages were producing or present-
ing SDF-1 (Figure 4c; lower panels).
To demonstrate the critical role of SDF-1-mediated stem/
progenitor cell mobilization in the improved wound healing,
inactivation of SDF-1 was achieved by a local intradermal
injection of anti-SDF-1 antibodies in the group 4 mice once a
day until wounds were closed (Supplementary Figure S5
online). Control wounds were injected with the same volume
of mouse IgG at the same time. CD133þ CD31þ cells and
mRNA expression of CD133 were significantly decreased in
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Figure 1. Accelerated wound healing in mice treated with a combination of low-dose tacrolimus (T) and AMD3100 (AMD). (a) The model: on day 0, four
circular excisional wounds were created in C57BL/6 or CD133þ /C-L mice. (b) Wound measurements. Wound areas were determined using Adobe Photoshop
software (Adobe System, San Jose, CA). (c) Early healing. Representative photographs of wounds in mice (n¼6) showing striking differences beginning at
day 5. (d) Quantitative analysis of wound closure in mice (n¼6). *Po0.05. (e) Hematoxylin and eosin microphotographs of wounds at day 5. Scale bar¼ 200mm.
(f) The splinted wound model. (g) Macroscopic analysis of skin wound healing in the splinted mice. (h) Quantitative analysis of wound closure in the splinted mice
(n¼ 6). All data represent means ±SEM. *Po0.05.
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the wounds receiving anti-SDF-1 antibodies at 5 days after
injury. By contrast, the number of these cells increased in the
wounds treated with control mouse IgG (Supplementary
Figure S5d-e online). However, the number of F4/80þ
macrophages remained the same, indicating that they were
mobilized by a different mechanism. These diminished stem
cell responses led to the delayed wound closure in the dual
drug–treated mice (Supplementary Figure S5c online). Thus,
inactivation of SDF-1 eliminated the beneficial effect of dual
drug therapy.
Dual drug treatment increased the expression of angiogenic
cytokines at 5 days after wounding
Semiquantitative PCR analysis of the granulation tissues
showed that mRNA expression of the angiogenic cytokines,
vascular endothelial growth factor, and basic fibroblast growth
factor, and an important stem cell mobilizing and homing
factor, hepatocyte growth factor (HGF), were all significantly
increased in the group 4 mice compared with group 1, 2, and
3 (Figure 5a and b). Immunofluorescence staining demon-
strated that the number of HGF-positive cells was significantly
greater in the granulation tissues recovered from the group 4
mice 5 days after injury. Similarly, the number of CD31þ
endothelial cells in the granulation tissues was markedly
increased in the group 4 mice compared with the group 1,
2, and 3. Some of these CD31þ cells formed tube-like
structures (Figure 5c; right panels) in the granulation tissues,
which also stained for HGF, emphasizing the important role of
HGF in neovascularization. The tubular structures also co-
stained with CD133 (Figure 3b; right panels), suggesting that
HGF may be involved in the differentiation of endothelial cells
from CD133 precursors.
We sought evidence of enhanced production of cells con-
tributing to matrix and indeed immunofluorescence staining
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demonstrated that the number of a-smooth muscle actin–
positive myofibroblast cells increased in the granulation
tissues recovered from the group 2 and 3 mice compared
with the group 1, whereas group 4 mice clearly recruited more
myofibroblasts in the granulation tissues at 5 days (Figure 5c;
lower panels).
Lineage tracing demonstrated the critical role of CD133 stem
cells in improving wound healing by the combination of
AMD3100 and low-dose tacrolimus
Lineage tracing studies were performed to confirm the
critical role of CD133 stem cells in wound healing. Adult
CD133 positive-Cre-nuclear(n)LacZ (CD133þ /C-L) mice con-
taining the Rosa26GFP reporter allele (CD133þ /C-L X mTmG
offspring) were used. CreERT2 activity was induced with
tamoxifen 7 days before wounding (Figure 6a). In this mouse
model, progenitor CD133 cells were lacZ positive, whereas
the CD133 progeny were GFP positive. LacZ- and GFP-
positive cells were observed only in the hair follicles of
intact mouse skins (Figure 6b) as reported by others
(Charruyer et al., 2012).
Both lacZ- and GFP-positive cells were increased in the
granulation tissues at 5 days after wounding (Supplementary
Figure S6 online; upper and middle panels). The numbers of
lacZ- and GFP-positive cells were significantly higher in the
granulation tissues recovered from the group 2 and 3 mice
compared with the group 1, but greatest numbers of lacZ- and
GFP-positive cells were found in the granulation tissues of the
group 4 mice (Supplementary Figure S6 online). Most of the
LacZ-positive cells disappeared at 15 days in groups 1, 2, and
3, while their progeny CD133 GFP-positive cells remained in
the healed tissues (Figure 6c). However, in group 4 mice,
newly generated vasculature, epidermis, and hair follicles
remained positive for both LacZ and GFP (Figure 6d). These
results imply that pharmacologically mobilized CD133 stem
cells and their progeny are the principle contributors to skin
regeneration.
DISCUSSION
AMD3100 (Plerixafor or Mozobil) is a direct antagonist of
C-X-C chemokine receptor type 4 and has been used clinically
to drive hematopoietic stem cells out of the BM into the
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peripheral blood of humans where they can be recovered and
preserved until the completion of ablative irradiation and/or
chemotherapy. AMD3100 has also found application in the
repairs of tissue injuries (Jujo et al., 2010, 2013; Nishimura
et al., 2012). The injection of a single dose augmented the
mobilization of BM-derived endothelial progenitor cells,
which was associated with more rapid neovascularization
and functional recovery after myocardial infarction in mice
(Jujo et al., 2010). After ischemia/reperfusion injury (Jujo et al.,
2013), acute injections redistributed proangiogenic BM cells
to ischemic myocardium in an endothelial nitric oxide
synthase–dependent fashion and promoted the recovery of
cardiac function in mice. A single topical application of
AMD3100 promoted wound healing in diabetic mice
(Nishimura et al., 2012), which was associated with increased
cytokine production, increased numbers of BM endothelial
progenitor cells, and increased activity of fibroblasts and
monocytes/macrophages. Both angiogenesis and vasculo-
genesis were increased (Nishimura et al., 2012). Our results
confirmed and significantly extended these findings. Indeed,
AMD3100 monotherapy resulted in mild recruitment of stem
cells into the wound sites and shortened wound healing to a
modest degree (Figure 3b). Our important contribution is the
finding that combining low-dose tacrolimus with AMD3100
led to a much greater accumulation of stem cells and more
rapid regeneration of normal skin in our rodent models of full-
thickness skin excision. Tacrolimus given at one tenth the
immunosuppressive dose had profound, synergistic effects
with AMD3100 in the recruitment of stem cells into the blood
stream and wounds, particularly those carrying combined
monocyte and SDF-1 markers.
Tacrolimus is a calcineurin inhibitor and a potent immuno-
suppressive drug. But surprisingly, it also augments cell
regeneration and repair in subimmunosuppressive dosages
(Francavilla et al., 1989; Carroll et al., 1994; Gold, 1997).
Low dosages (0.1 mg kg1), but not standard immunesup-
pressive dosages (1.0 mg kg1), of tacrolimus promoted
healing of colon anastomoses in rats (Kiyama et al., 2002).
Tacrolimus treatment facilitated the healing of lower extremity
skin ulcers in a 75-year-old woman with lichen planus and
diabetes mellitus (Miller, 2008). Bai et al. (Bai et al., 2010)
showed in vitro that low (20 ng ml1)- but not high
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(2,000 ng ml 1)-dose tacrolimus treatment skewed BM-
derived macrophage polarization toward an active M2
macrophage phenotype. In our study, we also demonstrated
that low-dose tacrolimus improved skin wound healing and
was associated with a significant increase in the numbers of
macrophages in the skin wound co-staining with SDF-1 on the
fifth postoperative day. We could not distinguish whether
these cells secreted SDF-1 or presented it on their cell
membranes.
To expand on the importance of SDF-1, we inactivated it by
local intradermal injection of anti-SDF-1 antibodies. This led
to diminished stem cell responses and to the delayed wound
closure in the dual drug–treated mice. Control dual-treated
mice injected with equal amounts of isotype control IgG
healed normally, thereby emphasizing the critical role of
SDF-1-mediated stem/progenitor cell mobilization in the
improved wound healing. Thus, a strong ‘‘push’’ of stem cells
from their BM niches by AMD3100 and a strong ‘‘pull’’ of
circulating stem cells by factors in the wound sites enhanced by
low-dose tacrolimus best explains why there was a greater accu-
mulation of stem cells in wound sites and more rapid restoration
of normal skin with dual AMD3100/tacrolimus treatment.
The recruitment of stem cells by dual drugs was associated
with elevated expression of vascular endothelial growth factor,
basic fibroblast growth factor, and HGF mRNA in the wounds.
Interestingly, anti-HGF antibody co-stained with CD31þ cells
that were also CD133þ (Figure 5c). HGF has many stimula-
tory actions and has been shown to be a potent regulator of
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hematopoietic stem and progenitor cells’ proliferation and
differentiation (Nishino et al., 1995), as well as a powerful
stimulator of angiogenesis (Ding et al., 2003). It also has been
shown that HGF exerts a strong chemotactic effect on MSCs in
a wound-healing model (Neuss et al., 2004). Thus, dual drug
treatment facilitated the accumulation of SDF-1-producing
macrophages, which led to the recruitment of more stem
cells. In turn, the elaboration of HGF, and other autocrine or
paracrine mediators produced more proangiogenic factors
completing positive feedback loops (Figure 6e).
CD133 stem cells have a vital role in neovascularization
and hair follicle regeneration, which is essential for perfect
skin regeneration (Sun et al., 2011). Such cells have the
potential to differentiate along endothelial lineages in vitro
(Hollemann et al., 2012) and are known to migrate to sites of
neovascularization in response to mediators (vascular endo-
thelial growth factor and SDF-1). Immunofluorescence double
staining demonstrated that many CD133 cells co-stained with
CD31 (Figure 2b), an early endothelial cell marker. During the
maturation process, the CD133 marker waned and the CD31
phenotype gained (Hollemann et al., 2012). Enhanced angio-
genesis was associated with increased numbers of infiltrating
CD133þCD31þ progenitor cells in the wound sites and
strengthens the role of these cells in neovascularization.
Epidermal and hair follicle stem cells can undergo repro-
gramming to become repopulating epidermal progenitor cells
following wounding (Ito et al., 2005). Lineage analysis has
also demonstrated that follicles can arise from cells outside of
the hair follicle stem cell niche, suggesting that cells found in
the epidermis can assume a hair follicle stem cell phenotype
(Ito et al., 2007). A recent study reported that CD133 is a
marker for long-term repopulating murine epidermal stem
cells and CD133þ keratinocytes formed both hair follicles
and epidermis after injection into immunodeficient mice
(Charruyer et al., 2012). Our lineage tracing studies
demonstrated the presence of CD133þ cells in the hair
follicles of intact skin (Figure 6b). Although it is clear from
our lineage tracing studies that increased numbers of CD133
stem cells contributed to hair follicle regeneration and that
these cells were liberated from the BM by dual treatment, it is
possible that these CD133þ stem cells originate from normal
skin. We consider this unlikely for several reasons. Our lineage
tracing study did not show the expansion of CD133þ cells in
the hair follicles of intact skin adjacent to the wound sites.
Instead, CD133þ cells accumulated in the central granulation
tissues rather than the wound edges. Further, the number
of CD133þ cells in the wound sites correlated with the
number of CD133þ cells in peripheral blood.
The mechanisms responsible for the BM stem cells-mobiliz-
ing effects of low-dose tacrolimus remain fascinating and
unknown, but are probably unrelated to calcineurin inhibition
for several reasons. Low dosages, such as those that we used,
do not inhibit calcineurin. Cyclosporin A, a known calcineurin
inhibitor was ineffective. Finally, tacrolimus is known to have
cellular binding proteins. A recent paper (Spiekerkoetter et al.,
2013) reported that low-dose tacrolimus activated bone
morphogenic protein receptor 2 signaling, which may stimu-
late SDF-1 expression in macrophages.
In conclusion, we report here that a previously unreported
therapeutic strategy designed to mobilize endogenous stem
cells into skin wounds results in better and faster healing. The
magnitude of both the quantitative and qualitative differences
is highly significant and is greater than that found in any other
study of wound healing in normal animals. Our studies do not
disclose the molecular mechanisms that differentiate these
malleable cells into tissue components, such as those reported
for Fgf9 (Gay et al., 2013) or Sept4/ARTS (Fuchs et al., 2013).
However, the differentiating steps leading to healing with
reestablishment of skin appendages proceeded faultlessly
when there were abundant stem cells producing almost
normal skin. This is our report demonstrating the profound
synergistic effects of AMD3100 and low-dose tacrolimus in
the mobilization, recruitment, and retention of endogenous
stem cells leading to faster healing and differentiation into all
of the tissues present in normal skin. These findings may be
easily applied in the clinic.
MATERIALS AND METHODS
Details can be obtained from the online Supplementary Materials
online.
Animals
C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME), CD133þ /C-L
mice (obtained from St Jude Children’s Research Hospital, Memphis,
TN) (Zhu et al., 2009), mT/mG mice (kindly provided by Dr Steven D.
Leach; Muzumdar et al., 2007), and DA (RT1Aa) rats (Harlan Sprague-
Dawley, Indianapolis, IN) were cared for according to NIH guidelines
and under a protocol approved by the Johns Hopkins University
Animal Care Committee.
In vivo excisional wound model
Full-thickness wounds were created in the dorsal skin (Tomlinson
and Ferguson, 2003) of mice (Figure 1a), splinted mice (Figure 1f;
Galiano et al., 2004), and rats (Supplementary Figure S1a online)
with a sterile disposable biopsy punch (5 mm in diameter; Figure 1a
and Supplementary Figure S1a online). The animals were injected
subcutaneously with AMD3100 or tacrolimus.
Histology and microscopy
GFP microscopy, LacZ analysis, and hematoxylin and eosin staining
were performed on skin sections from tamoxifen-treated CD133þ /
C-L mice. For hair neogenesis analysis, the number of regenerated
hair follicles in the wound area (hematoxylin and eosin-stained)
was quantified in a double-blind fashion. Immunofluorescence
staining was performed using anti-CD133, -CD34, -c-Kit, -SDF-1,
-F4/80, -a-smooth muscle actin, -CD31, or -HGF antibodies.
Flow cytometry
Single-cell suspension of peripheral blood was analyzed for expres-
sion of lineage-negative c-Kitþ , CD34þ , and CD133þ stem cell
markers by flow cytometry using CELLQuest software (Becton-
Dickinson, Bedford, MA).
Semiquantitative reverse transcription–PCR analysis
Total RNAs were extracted from the skin specimens and reverse
transcription–PCR was performed. The expression levels of target
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mRNA were quantified by densitometry and normalized with the
corresponding internal control.
Statistics
Continuous variables were presented as the mean±SEM. The
Student’s t-test or one-way analysis of variance was performed as
described in the Supplementary Information online. The Po0.05
was considered significant.
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